이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Guardant Health 과거 수익 실적

과거 기준 확인 0/6

Guardant Health의 수입은 연평균 -33%의 비율로 감소해 온 반면, Healthcare 산업은 수입이 연평균 5.6%의 비율로 증가했습니다. 매출은 연평균 25.3%의 비율로 증가해 왔습니다.

주요 정보

-29.5%

수익 성장률

-25.9%

EPS 성장률

Healthcare 산업 성장	8.5%
매출 성장률	23.9%
자기자본 수익률	n/a
순이익	-76.2%
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 24

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Aug 21

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Jul 31

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jul 12

Guardant: Double-Digit Sales Projections Come At A Cost

Jun 06

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Jun 04

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

May 14

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Mar 29

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21

수익 및 비용 분석

Guardant Health 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:GH 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	644	-491	463	349
31 Mar 24	604	-461	454	356
31 Dec 23	564	-479	451	365
30 Sep 23	536	-432	458	381
30 Jun 23	510	-508	474	387
31 Mar 23	482	-665	477	382
31 Dec 22	450	-655	464	369
30 Sep 22	431	-606	442	338
30 Jun 22	408	-551	420	309
31 Mar 22	391	-419	400	287
31 Dec 21	374	-406	399	263
30 Sep 21	344	-409	398	230
30 Jun 21	324	-379	390	196
31 Mar 21	298	-336	357	168
31 Dec 20	287	-254	299	150
30 Sep 20	271	-185	239	135
30 Jun 20	258	-120	183	124
31 Mar 20	245	-77	154	107
31 Dec 19	214	-76	140	86
30 Sep 19	184	-76	128	77
30 Jun 19	145	-87	115	67
31 Mar 19	111	-97	102	59
31 Dec 18	91	-85	90	51
30 Sep 18	78	-75	74	42
30 Jun 18	67	-84	76	35
31 Mar 18	57	-83	69	29
31 Dec 17	50	-89	66	26
31 Dec 16	25	-46	36	11

양질의 수익: GH 은(는) 현재 수익성이 없습니다.

이익 마진 증가: GH 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: GH 은(는) 수익성이 없으며 지난 5년 동안 연간 33% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 GH 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: GH 은(는) 수익성이 없어 지난 해 수익 성장을 Healthcare 업계( 15.1% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: GH 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Guardant Health 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Recent updates

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Price target increased by 7.0% to US$41.85

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

High number of new directors

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Guardant: Double-Digit Sales Projections Come At A Cost

Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer

Price target decreased by 7.1% to US$42.94

Full year 2023 earnings: EPS misses analyst expectations

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Guardant Health, Inc. to Appeal Federal District Court Verdict

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Now 20% undervalued after recent price drop

Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan

Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Is Guardant Health (NASDAQ:GH) A Risky Investment?

Consensus estimates of losses per share improve by 14%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan

Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index

A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Price target decreased by 7.1% to US$52.82

Guardant Health, Inc. Announces Management Changes

Chief Legal Officer exercised options and sold US$90k worth of stock

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

High number of new directors

Co-CEO & Director recently bought US$2.5m worth of stock

Chief Information Officer recently sold US$193k worth of stock

Consensus EPS estimates upgraded to US$4.60 loss, revenue downgraded

Full year 2022 earnings: EPS misses analyst expectations

Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer

Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer

Price target decreased by 8.4% to US$63.56

Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery

Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer